Sacituzumab govitecan (solution)
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab , and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity[1].
Product Specifications
CAS Number
1491917-83-9
Product Name Alternative
IMMU-132 (solution)
UNSPSC
12352203
Hazard Statement
H341, H360, H373
Target
Antibody-Drug Conjugates (ADCs) ; TROP2
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sacituzumab-govitecan-solution.html
Purity
99.10
Solubility
10 mM in DMSO
Smiles
[Sacituzumabgovitecan(solution)]
Precautions
H341, H360, H373
References & Citations
[1]Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26 (5) :919-31.|[2]Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10;11 (10) :942]. Oncotarget. 2015;6 (26) :22496-22512.|[3]Cardillo TM, et al., Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26 (5) :919-31.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
